Sentynl Therapeutics
CA - Solana Beach
BiotechnologyFocus: Small Molecules
Sentynl Therapeutics is a life sciences company focused on Small Molecules.
NeurologyOncologyRare DiseasesUnknown
Funding Stage
PUBLIC
Open Jobs
3
Products & Portfolio (3)
1 discontinued product not shown
NULIBRY
fosdenopterin hydrobromide
Peak
INTRAVENOUS · POWDER
MOCS1 gene leading to deficient MOCS1A/B dependent synthesis of the intermediate substrate, cPMP. Substrate replacement therapy with NULIBRY provides an exogenous source of cPMP, which is converted to molybdopterin. Molybdopterin is then converted to molybdenum cofactor, which is needed for the activation of molybdenum-dependent enzymes, including sulfite oxidase (SOX), an enzyme that reduces levels of neurotoxic sulfites.
mortality in patients with molybdenum cofactor deficiency (MoCD) Type A
2021
8
ZOKINVY
lonafarnib
Peak
SMORAL · CAPSULE
Farnesyltransferase Inhibitors
2020
8
ZYCUBO
copper histidinate
Launch
SUBCUTANEOUS · POWDER
2026
18
Pipeline & Clinical Trials
copper histidinate
Menkes DiseaseClinical Trials (1)
NCT04074512Copper Histidinate Treatment for Menkes Disease
N/ALong Term Follow-Up
Menkes DiseaseClinical Trials (1)
NCT04337684Long Term Follow-up on Menkes Disease Patients
N/AOpen Jobs (3)
Interview Prep Quick Facts
Founded: 2015
Portfolio: 4 approved products, 2 clinical trials
Top TAs: Oncology, Neurology
Publications: 1 in PubMed
Open Roles: 3 active jobs
Portfolio Health
Launch1 (25%)
Peak2 (50%)
LOE Approaching1 (25%)
4 total products